Imagion Biosystems has announced a letter to shareholders regarding the 28 October 2019 announcement of a renounceable pro-rata offer.
Read the letter to shareholders.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal